Page 2 - Replimune Group News Today

In this article, we will take a look at the 12 best medical stocks to buy under $10. To skip our analysis of the latest trends, and market activity, you can go directly to see the 5 Best Medical Stocks to Buy Under $10. The healthcare sector spans medical stocks including biotechnology companies, health insurance […]

Loomis Sayles & Co. L P grew its stake in shares of Replimune Group, Inc. (NASDAQ:REPL – Free Report) by 8.7% during the 3rd quarter, HoldingsChannel.com reports. The fund owned 1,290,450 shares of the company’s stock after purchasing an additional 103,223 shares during the quarter. Loomis Sayles & Co. L P’s holdings in Replimune Group […]

Replimune Group (NASDAQ:REPL – Get Free Report) issued its earnings results on Thursday. The company reported ($0.77) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.89) by $0.12, Briefing.com reports. Replimune Group Stock Up 0.9 % Shares of REPL traded up $0.07 during trading hours on Friday, hitting $7.79. The stock had […]

By Dean Seal Disc Medicine has hired the former chief financial officer of Replimune Group and promoted one of its C-suite members to chief operating...

In this article, we will take a look at the 15 small-cap stocks with high potential. To skip our analysis of the latest trends, and market activity, you can go directly to see the 5 Small-Cap Stocks with High Potential. Nearly 9,500 stocks trade on major U.S. stock exchanges with nearly half of them having […]

In this article, we will take a look at the 15 small-cap stocks with high potential.

The combination of RP1 and cemiplimab provided a numerical, but not statistically significant, improvement in response rates vs cemiplimab alone in patients with locally advanced or metastatic cutaneous squamous cell carcinoma, missing the primary end points of the phase 2 CERPASS trial.

Replimune Group (NASDAQ:REPL – Free Report) had its target price decreased by Barclays from $50.00 to $13.00 in a research report report published on Wednesday morning, Benzinga reports. Barclays currently has an overweight rating on the stock. A number of other brokerages also recently weighed in on REPL. Wedbush reaffirmed an outperform rating and issued […]

Camber Capital Management LP increased its holdings in shares of Replimune Group, Inc. (NASDAQ:REPL – Free Report) by 24.0% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,550,000 shares of the company’s stock after acquiring an additional 300,000 shares […]